K. McClelland

发表

FKBPL and Peptide Derivatives: Novel Biological Agents That Inhibit Angiogenesis by a CD44-Dependent Mechanism

D. Hirst, H. McCarthy, D. Waugh, 2011, Clinical Cancer Research.

Cancer Therapy : Preclinical FKBPL and Peptide Derivatives : Novel Biological Agents That Inhibit Angiogenesis by a CD 44-Dependent Mechanism

D. Hirst, H. McCarthy, D. Waugh, 2011 .

That Inhibit Angiogenesis by a CD 44-Dependent Mechanism FKBPL and Peptide Derivatives : Novel Biological Agents

D. Hirst, H. McCarthy, D. Waugh, 2011 .

A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling.

D. Hirst, H. McCarthy, C. Scott, 2008, Endocrinology.

Identification and Structure-Guided Development of Pyrimidinone Based USP7 Inhibitors.

Scarlett A Dvorkin, Colin R. O'Dowd, T. Harrison, 2018, ACS medicinal chemistry letters.

Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily.

J. Boros, D. M. Andrews, R. Ward, 2017, ACS chemical biology.

BRCA1, FANCD2 and Chk1 are potential molecular targets for the modulation of a radiation-induced DNA damage response in bystander cells.

K. Rothkamm, K. Prise, S. A. Al Rashid, 2015, Cancer letters.

Discovery and characterization of highly potent and selective allosteric USP7 inhibitors.

Colin R. O'Dowd, T. Harrison, Elias Arkoudis, 2018, Nature chemical biology.

Abstract LB-257: Discovery and characterization of novel, highly potent and selective USP7 inhibitors

Alan P. Brown, Colin R. O'Dowd, F. Burkamp, 2015 .

Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen

J. F. Burrows, H. McCarthy, L. McClements, 2014, Oncogene.